‘Missing Adenocarcinomas’: Are They a Real Problem in Cervical Cancer Screening in Brazil?

Diama Bhadra Vale; Joana Fróes Bragança; Luiz Carlos Zeferino

doi:10.1055/s-0039-1698772

Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics, Table of Contents

CC BY 4.0 · Rev Bras Ginecol Obstet 2019; 41(10): 579-580
DOI: 10.1055/s-0039-1698772

Editorial

Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil

‘Missing Adenocarcinomas’: Are They a Real Problem in Cervical Cancer Screening in Brazil?

Authors

Diama Bhadra Vale

¹Department of Obstetrics and Gynecology, Universidade Estadual de Campinas, Campinas, SP, Brazil
Joana Fróes Bragança

¹Department of Obstetrics and Gynecology, Universidade Estadual de Campinas, Campinas, SP, Brazil
Luiz Carlos Zeferino

¹Department of Obstetrics and Gynecology, Universidade Estadual de Campinas, Campinas, SP, Brazil

Abstract

Full Text

References

References
1 World Health Organization. Comprehensive cervical cancer control: a guide to essential practice. 2^nd ed. Geneva: WHO; 2014
2 Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer 2009; 45 (15) 2640-2648 . Doi: 10.1016/j.ejca.2009.07.018
3 Ministério da Saúde. Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2018: Incidência de Câncer no Brasil. Rio de Janeiro, RJ: INCA; 2017. https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-incidencia-de-cancer-no-brasil-2018.pdf . Accessed July 12, 2018.
4 Vaccarella S, Laversanne M, Ferlay J, Bray F. Cervical cancer in Africa, Latin America and the Caribbean and Asia: Regional inequalities and changing trends. Int J Cancer 2017; 141 (10) 1997-2001 . Doi: 10.1002/ijc.30901
5 Koliopoulos G, Nyaga VN, Santesso N. , et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev 2017; 8: CD008587 . Doi: 10.1002/14651858.CD008587.pub2
6 Ronco G, Dillner J, Elfström KM. , et al; International HPV screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014; 383 (9916): 524-532 . Doi: 10.1016/S0140-6736(13)62218-7
7 Zappa M, Visioli CB, Ciatto S, Iossa A, Paci E, Sasieni P. Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence. Br J Cancer 2004; 90 (09) 1784-1786 . Doi: 10.1038/sj.bjc.6601754
8 Mitchell H, Hocking J, Saville M. Improvement in protection against adenocarcinoma of the cervix resulting from participation in cervical screening. Cancer 2003; 99 (06) 336-341 . Doi: 10.1002/cncr.11835
9 Castanon A, Landy R, Sasieni PD. Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix?. Int J Cancer 2016; 139 (05) 1040-1045 . Doi: 10.1002/ijc.30152
10 Roma AA, Fadare O. The pattern is the issue: recent advances in adenocarcinoma of the uterine cervix. Virchows Arch 2018; 472 (06) 897-905 . Doi: 10.1007/s00428-018-2312-6
11 Stolnicu S, Hoang L, Chiu D. , et al. Clinical outcomes of HPV-associated and unassociated endocervical adenocarcinomas categorized by the International Endocervical Adenocarcinoma Criteria and Classification (IECC). Am J Surg Pathol 2019; 43 (04) 466-474 . Doi: 10.1097/PAS.0000000000001224
12 Mikami Y, Kiyokawa T, Hata S. , et al. Gastrointestinal immunophenotype in adenocarcinomas of the uterine cervix and related glandular lesions: a possible link between lobular endocervical glandular hyperplasia/pyloric gland metaplasia and ‘adenoma malignum’. Mod Pathol 2004; 17 (08) 962-972 . Doi: 10.1038/modpathol.3800148
13 Kuragaki C, Enomoto T, Ueno Y. , et al. Mutations in the STK11 gene characterize minimal deviation adenocarcinoma of the uterine cervix. Lab Invest 2003; 83 (01) 35-45
14 Nofech-Mozes S, Khalifa MM, Ismiil N. , et al. Detection of HPV-DNA by a PCR-based method in formalin-fixed, paraffin-embedded tissue from rare endocervical carcinoma types. Appl Immunohistochem Mol Morphol 2010; 18 (01) 80-85 . Doi: 10.1097/PAI.0b013e3181ae7240
15 Pirog EC, Lloveras B, Molijn A. , et al; RIS HPV TT study group. HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Mod Pathol 2014; 27 (12) 1559-1567 . Doi: 10.1038/modpathol.2014.55
16 Cooper K, Herrington CS, Lo ES, Evans MF, McGee JO. Integration of human papillomavirus types 16 and 18 in cervical adenocarcinoma. J Clin Pathol 1992; 45 (05) 382-384 . Doi: 10.1136/jcp.45.5.382
17 Schiffman M, Doorbar J, Wentzensen N. , et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers 2016; 2: 16086 . Doi: 10.1038/nrdp.2016.86
18 Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer 2013; 49 (15) 3262-3273 . Doi: 10.1016/j.ejca.2013.04.024
19 Basu P, Ponti A, Anttila A. , et al. Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report. Int J Cancer 2018; 142 (01) 44-56 . Doi: 10.1002/ijc.31043
20 Basu P, Mittal S, Bhadra Vale D, Chami Kharaji Y. Secondary prevention of cervical cancer. Best Pract Res Clin Obstet Gynaecol 2018; 47: 73-85 . Doi: 10.1016/j.bpobgyn.2017.08.012